Analysis of prognosis and influencing factors of secondary cytoreductive surgery combined with chemotherapy for recurrent ovarian cancer
10.3760/cma.j.cn.115807-20210126-00030
- VernacularTitle:二次肿瘤细胞减灭术联合化疗治疗复发性卵巢癌的预后与影响因素分析
- Author:
Guangcai PENG
1
;
Jinhong ZHOU
;
Shumei ZENG
;
Yanfei SUN
;
Sufei WANG
Author Information
1. 浙江大学医学院附属浙江医院妇科，杭州 310000
- Keywords:
Secondary cytoreductive surgery;
Chemotherapy;
Recurrent ovarian cancer
- From:
Chinese Journal of Endocrine Surgery
2021;15(3):243-247
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the prognosis and influencing factors of secondary cytoreductive surgery (SCS) combined with chemotherapy in the treatment of recurrent ovarian cancer.Methods:A total of 102 patients with recurrent ovarian cancer admitted to our hospital from Jun. 2012 to Jun. 2015 were selected and grouped according to treatment methods. 31 patients who received paclitaxel/carboplatin (TC) chemotherapy were included in the control group, and 71 patients who received SCS combined with TC chemotherapy were included in the observation group. Clinical efficacy and 5-year survival outcome of the two groups after treatment, were compared and factors affecting the prognosis of the observation group were analyzed.Results:The total effective rate, 1-year survival rate, 3-year survival rate, and 5-year survival rate of the observation group were significantly higher than those of the control group. The median survival time of the observation group was 52 months and was significantly longer than that of the control group by 17 months ( P<0.05) ; There was no statistical difference between the death group and the survival group in terms of age, pathological type, tissue differentiation, recurrence tumor size, or location of recurrence tumors. The number of patients with FIGO stage IV, more than 3 recurrent tumors, ascites and residual lesion size >1 cm in the death group were significantly larger than those in the survival group. The serum CA125 level of patients in the death group was significantly higher than that in the survival group. Logistic regression analysis showed that the number of recurring tumors>3, with ascites, and residual lesions>1 cm, and high level of CA125 were independent risk factors for death after SCS combined with TC chemotherapy ( P<0.05) . Conclusions:SCS combined with chemotherapy can effectively improve the therapeutic effect, relieve the clinical symptoms, improve the survival rate of patients, and prolong the survival time of patients. The prognosis of SCS combined with chemotherapy is affected by the number of recurrent tumors, the presence or absence of ascites, the size of residual lesions, and CA125 level. The prognosis and survival of patients can be improved by adopting appropriate treatment.
